We sit at the frontier of what medicine can measure. We bring you that access — filtered through rigorous clinical judgment, not trend-chasing.
There is a gap between what medical science can now detect and what most people are offered. Breakthrough diagnostics — capable of identifying cancer before symptoms, measuring biological age directly, mapping your genome for lifetime risk — exist and are clinically validated. They are simply not in the standard pathway.
Breeoot closes that gap. We monitor the frontier, evaluate the evidence, and offer you access when the science is ready — not before.
Galleri by GRAIL
"Is there a cancer signal in my blood right now?"
The Galleri test screens for more than 50 types of cancer from a single blood draw, by detecting abnormal cell-free DNA shed into the bloodstream by tumour cells. For many of the cancers it identifies — pancreatic, ovarian, oesophageal — standard screening does not exist. For these diseases, early detection is often the only meaningful intervention.
Where clinically indicated, we offer Galleri as part of your assessment. We interpret results in context, coordinate follow-up, and ensure that a positive signal leads to a defined clinical pathway — not confusion.
Epigenetic clock analysis — GrimAge & PhenoAge
"How old is my body, biologically — regardless of what my birth certificate says?"
Chronological age tells you how long you've been alive. Biological age tells you how your cells and tissues are actually ageing. These can diverge by a decade or more, in either direction, depending on genetics, lifestyle and metabolic health.
We use validated epigenetic clock analyses — including GrimAge and PhenoAge, the most predictive current tools — to measure your biological age at the cellular level. The result is both a snapshot and a tracking metric: as your protocols improve your metabolic and inflammatory markers, your biological age moves with them. You can see your biology ageing more slowly.
Full Exome Sequencing — interpreted by a clinical expert
"What risks are written into your genome — and which ones can we actually do something about?"
Most genetic tests on the market — including widely advertised consumer products — scan a limited set of pre-selected markers. They are built to find what they already know to look for. Full exome sequencing is categorically different: it reads every protein-coding region of your genome, approximately 20,000 genes, covering the ~2% of your DNA where around 85% of known disease-causing mutations occur. It surfaces risk that no targeted panel would find, because no panel was designed to look for it.
The difference between an exome and a standard genetic screen is not incremental. Consumer tests typically examine a few hundred thousand known variants out of three billion base pairs. Targeted clinical panels go further, but remain confined to genes linked to specific conditions someone already suspected. An exome looks at the whole coding genome — the full text, not just the chapters someone highlighted in advance.
An unreviewed exome generates thousands of variants. Raw data is not clinical intelligence. The value is in what a trained clinical geneticist does with it: distinguishing pathogenic variants from variants of uncertain significance, correlating genetic findings with your phenotype, family history and existing biomarker results, and translating that into a management plan with a specific next step attached. Without expert review, an exome is an unanswered question.
Breeoot applies a strict clinical filter. We focus exclusively on variants where science has established pathogenic classification and where a meaningful clinical action exists — a protocol, a medication, a surveillance strategy, a lifestyle modification with demonstrated impact. Variants of uncertain significance — mutations science cannot yet attribute consequence to, or where no intervention pathway exists — are noted but are not the subject of clinical management. The goal of genomics is to reduce your risk, not to generate anxiety about unknowns. We do not chase what we cannot address.
Three tests. Ordered once. Clinically decisive.
"What are the specific risks I was born with — and that standard panels will never show me?"
These are not experimental tests. They are clinically validated, available today, and each has an outsized impact on long-term health trajectory. The reason most people have never had them is not medical — it is systemic. Standard panels don't include them. Most practices don't order them. That gap is what we close.
The primary genetic determinant of late-onset Alzheimer's disease. Approximately 25% of the population carries one copy; around 2–3% carry two. APOE4 also affects cardiovascular risk independently. Carriers benefit from specific dietary, metabolic and cardiovascular protocols shown to meaningfully shift downstream risk — but only if they know they carry it. A single test. Known for life.
The most clinically meaningful lipid marker available — measuring the number of atherogenic particles in circulation, not just their cholesterol content. ApoB is more predictive of cardiovascular events than LDL-C and is now the primary lipid target recommended by major cardiovascular guidelines, including the European Society of Cardiology. Most Israeli practices still report LDL-C alone. We report ApoB as standard.
A genetically determined, causal risk factor for myocardial infarction and aortic stenosis. Roughly 1 in 5 people carry clinically elevated levels. It does not respond meaningfully to diet or lifestyle — but it is measurable with a single blood test, and it should be measured once in every adult's life. The majority of people reading this have never had it done. We include it as a baseline.
The data a snapshot can never give you.
"What is actually happening in my body across a full day, a full night — not just during a clinic visit?"
A single blood draw is a photograph. Continuous monitoring is a film. The clinical findings that matter most — glucose dysregulation, nocturnal hypertension, sleep-disordered breathing — are almost entirely invisible to snapshot testing. They require time-series data, collected in the conditions of your actual life.
A person with a perfectly normal fasting glucose can show dramatic post-meal spikes and overnight lows that standard testing never captures. CGM makes glucose dynamics visible across real meals, real stress, real sleep.
A clinic blood pressure reading captures one moment in one environment. ABPM records pressure across a full 24-hour cycle — detecting nocturnal hypertension, white-coat effect, early-morning surges, and the absence of the normal overnight dip.
Sleep-disordered breathing affects a significant proportion of adults and is one of the most underdiagnosed contributors to hypertension, metabolic dysfunction and cognitive decline. An at-home sleep study captures apnoea-hypopnoea index, oxygen saturation patterns, and sleep stage data — in your actual sleep environment.
Access without rigour
is not medicine.
It is noise.
Every diagnostic we offer has cleared an evidence bar: peer-reviewed validation, clinical utility — not just biological curiosity — and a defined pathway for what we do with the result.
We do not offer frontier tests because they are interesting. We offer them because the evidence says they change what we know, and what we know changes what we do.
Next step
A 30-minute call to understand your situation and whether membership is the right fit. No obligation.